Analysts Expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to Announce ($0.87) Earnings Per Share
Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price objective of $6.00 for the company and are predicting that the company will post ($0.87) EPS for the current quarter, according to Zacks. Zacks has also assigned HTG Molecular Diagnostics an industry rank of 91 out of 265 based on the ratings given to related companies.
HTGM has been the subject of several analyst reports. Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Rodman & Renshaw initiated coverage on HTG Molecular Diagnostics in a research note on Monday, August 22nd. They set a “buy” rating and a $5.00 target price for the company.
HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 2.46 on Monday. The stock’s market capitalization is $17.34 million. The stock has a 50 day moving average price of $2.45 and a 200 day moving average price of $2.68. HTG Molecular Diagnostics has a 52 week low of $2.03 and a 52 week high of $11.21.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Tuesday, August 9th. The company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.03. Equities analysts forecast that HTG Molecular Diagnostics will post ($3.58) EPS for the current year.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.